Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06866795 | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 1 | 42 | Geode Therapeutics Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06783829 |
| A Study of SHR-4394 Injection in Subjects With Prostate Cancer |
| recruiting |
| Phase 1 |
| 240 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Feb 27, 2025 |
| clinicaltrials |
| NCT06846424 | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | not yet recruiting | Phase 1 | 24 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06736054 | A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer | recruiting | Phase 1 | 8 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05656573 | CART-PSMA Cells for Advanced Prostate Cancer | recruiting | Phase 1 | 20 | Nova Therapeutics LLCINDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06683066 | Study on Human Bioequivalence of Triprerelin Acetate for Injection | recruiting | Phase 1 | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 71 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04652076 | GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab(GYNET) | active not recruiting | Phase 1 / Phase 2 | 240 | NETRIS PharmaINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05410717 | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | recruiting | Phase 1 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06415500 | A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 1 | May 16, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2025source: clinicaltrials